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One third of the population is affected by a
sleep disorder with a major social, medical, and
economic impact. Although very little is known
about the genetics of normal sleep, familial and
twin studies indicate an important influence of ge-
netic factors. Most sleep disorders run in families
and in several of them the contribution of genetic
factors is increasingly recognised. With recent ad-
vances in the genetics of narcolepsy and the role of
the hypocretin/orexin system, the possibility that
other gene defects may contribute to the patho-
physiology of major sleep disorders is worth in-
depth investigation.
Key words: HLA; narcolepsy; apnea; sleepwalking;
Kleine-Levin syndrome
In the past few years study of the molecular
basis of sleep-wakefulness regulation has become
a major and productive new field in neuroscience.
Starting in 1997 with our first report of mapping
genes for the amount and distribution of normal
sleep in mice and more recently with the discov-
ery of hypocretin/orexin deficiency by Emmanuel
Mignot’s laboratory in canine and human nar-
colepsy, the genetics of sleep and sleep disorders is
emerging as one of the most promising avenues in
our understanding of the basic mechanisms regu-
lating the complex behaviour sleep. Sleep disor-
ders are highly prevalent in the general population
and have dramatic health, social, and economic im-
pacts. Their treatments remain largely sympto-
matic owing to our ignorance of their molecular
pathophysiology. However familial and twin stud-
ies indicate the presence of important genetic fac-
tors in a large number of sleep disorders. Any dys-
function in the expression and the regulation of
sleep results in a complex sleep disorder that needs
integrated clinical and laboratory investigations.
The genetic dissection of well-characterised sleep
disorders might improve treatments and also pro-
vide fundamental insights into the underlying neu-
robiological bases of normal sleep and wakefulness. 
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Introduction
In 1986, Lugaresi and colleagues described a
53 year-old man who suffered from progressive
insomnia, dysautonomia, dysarthria, tremor, later
myoclonus and coma identifying the first sleep dis-
order for which a gene mutation has been identi-
fied: fatal familial insomnia (FFI) [1]. The major
features of FFI include a progressive reduction of
total sleep time, early disappearance of sleep spin-
dles, loss of slow wave sleep, and disintegration of
sleep cyclic organisation. This neurodegenerative
disorder is caused by a point mutation at codon 
178 of the Prion protein gene (PrP) and is respon-
sible for a degeneration of specific thalamic nuclei.
FFI affects both sexes equally in an autosomal
dominant manner with high penetrance and is 
uniformly fatal. The identified mutation at codon
178 results in the substitution of asparagine for 
aspartate. Familial Creutzfeld-Jacob disease (CJD)
is also associated with codon 178 mutation and
spongiform neurodegeneration leading to demen-
tia. However the FFI patients have a methionine
at codon 129 whereas CJD patients have a valine
at this position. Furthermore homozygosity at
codon 129 was associated with a more rapid dis-
ease course in both FFI and CJD patients and
lower age of onset in CJD patients [2].
Familial advanced sleep phase syndrome
(FASPS) is a highly penetrant autosomal dominant
abnormality of human circadian behaviour, which
produces a striking 4 hour advance of the daily
sleep-wakefulness rhythm. hPer2, a human ho-
molog of the Drosophila period gene was found to
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be mutated in affected members of one family with
FASPS [3]. A mutation at position 2106 (A to G)
of the casein kinase I epsilon (CKIe) binding re-
gion of hPer2 gene on chromosome 2 leads to a
substitution of a serine at amino acid 662 with a
glycine (S662G) and is therefore responsible for
FASPS. However not all the families tested, and
not all the members of the same family are linked
with the hPer2 locus, suggesting a genetic hetero-
geneity in FASPS. A recent study identified a 
missense mutation (T44A) in the human CKIdelta
gene in a family affected by FASPS. An A to G mu-
tation was identified, which causes a threonine-
to-alanine alteration at amino acid 44 in the mature
protein [4]. 
Molecular studies of primary insomnias are
very rare but a recent study reported a missense
mutation in a single patient with chronic insom-
nia. This mutation is a substitution of the amino
acid arginine for histidine at position 192 (R192H)
in the gene coding GABA-A beta3 subunit and 
alters the GABA-A receptor function in vitro [5].
The Beta-3 subunit is presumed to be implicated
in sleep processes by the observation that beta3
Knockout mice do not respond to the hypnotic 
action of oleamide [6].
Although highly rare, the three above exam-
ples together with a single narcolepsy case (see
below), clearly indicate that single gene defects can
produce substantial alterations of sleep. However
sleep is a highly complex behaviour and as such is
regulated by the action of many genes, environ-
ment, and gene-environment interactions. Sleep is
therefore a complex trait where the contribution
of susceptibility or protective genetic factors will
lead to either its normal variation in the popula-
tion (eg, short vs long sleepers), or to complex
sleep disorders such as narcolepsy.
Among highly prevalent sleep disorders the
contribution of genetic factors to parasomnias,
enuresis, restless legs syndrome and periodic limb
movements in sleep, and sleep apnoea syndromes
is now well demonstrated [see table 1]. Most of 
the available evidence comes from twin studies
where the relative contribution of genetic and en-
vironmental factors can be assessed. In the case of
simple disorders the concordance rate in mono-
zygotic twins (probability of same phenotype in
co-twins) is usually high (close to 100%), while in
complex disorders the concordance rate is usually
low (usually less than 50%). Therefore the concor-
dance rate in monozygotic twins reflects a direct
measure of respective contribution of genetic 
and environmental factors. In some disorders the
possibility of a single autosomal dominant gene 
effect cannot be ruled out. However even in these
disorders (eg, enuresis, restless legs syndrome), ge-
netic heterogeneity, phenocopy, incomplete pene-
trance, and variable expressivity may complicate
the discovery of the underlying genes. Only a few
sleep disorders have so far been investigated at the
molecular genetic level but narcolepsy represents
a unique model of a complex sleep disorder for
which substantial genetic evidence is available. As
discussed below even if the recently discovered
hypocretin-orexin deficiency is the best biological
marker of narcolepsy, the condition remains com-
plex in terms of its molecular basis. 
Narcolepsy-cataplexy is a rare but a highly dis-
abling disorder of vigilance affecting 0.02–0.06%
of the general population. The onset of the disease
is generally between 15 and 30 years old and af-
fects both sexes equally. Excessive daytime sleepi-
ness leads characteristically to irresistible and daily
repeated sleep periods while cataplexy is defined 
as a “sudden bilateral loss of postural muscle tone
Narcolepsy and genetic susceptibility to sleep disorders
Disorder family history twin studies linkage evidence candidate gene mode of transmission*
Sleepwalking Familial in up to 80%, 5 fold increased none HLA-DQB1*05 autosomal dominant
higher risk in concordance in MZ HLA-DQB1*04 or unknown [19–20]
1st degree relatives
Obstructive Higher risk in Higher concordance QTL on 1p, 2p, ApoE4 autosomal dominant
Sleep Apnoea 1st degree relatives in MZ for snoring 12p, 19p, 4q, 8q or unknown [21–22]
(in African-Americans)
Enuresis Over 75% in Higher concordance 8q, 13q, 12q,  22q11 None Autosomal dominant 
1st degree relatives in MZ [23]
RLS, PLMS 63–92% familial history Higher concordance 12q MAO-A Autosomal dominant 
in MZ or recessive [24–25]
Kleine-Levin Very few Familial cases No studies None HLA-DQB1*0201 Unknown [26]
Syndrome
RBD No studies Higher concordance None HLA-DQB1*05 Unknown [27]
in MZ HLA-DQB1*06
DSPS 50% have relatives No studies None HLA-DR1 Autosomal dominant
with similar symptoms hPER3, AA-NAT or unknown [28–29]
* based on pattern of transmission in families where the effect of a single gene is evident. MZ: monozygotic twins; QTL: 
quantitative trait loci; RLS: restless legs syndrome; PLMS: periodic limb movements in sleep; RBD: REM sleep behaviour disorder;
DSPS: delayed sleep phase syndrome; AA-NAT: arylalkylamine N-acetyltransferase 
Table 1.
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to sleep disorders.
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in association with intense emotion” but the pa-
tient remains totally conscious. 
Up to 10% of narcolepsies are familial. Dif-
ferent studies have shown that besides the typical
phenotype, attenuated forms of the condition
characterised by isolated excessive daytime sleepi-
ness do exist at much higher rates; 10–40% of first
degree relatives of narcoleptics may be affected.
However twins studies report 25–31% of concor-
dance suggesting a major contribution of environ-
mental factors.
Narcolepsy has one of the tightest associations
with a specific HLA allele. A first study reported
100% association between narcolepsy and the
HLA-DR2/DQw1 haplotype in Japanese patients
[7], a finding quickly confirmed in Caucasians. Four
alleles corresponding to DRB1*1501, DRB5*0101,
DQA1*0102, and DQB1*0602 are associated with
narcolepsy but DQB1*0602 constitute the major
HLA susceptibility allele across all ethnic groups.
The more striking fact is that 88–98% of patients 
affected by narcolepsy with clear cataplexy are HLA
DQB1*0602 positive. This allele strongly increases
the susceptibility for cataplexy although 41% of
patients without cataplexy are carriers. DRB1 and
DQB1 genes have been sequenced in narcolepsy 
patients but no mutation was identified suggesting
that they strongly confer susceptibility to deve-
lopment of the disease without their function 
being defective. Therefore non-HLA genes such 
as monoamine oxidase-A (MAO-A) [8], tumour
necrosis factor alpha (TNF-A) [9], TNFR2 (in
Japanese) [10], and catechol-O-metyltransferase
(COMT) [11] may in addition or independent of
HLA also be involved in susceptibility to narcolepsy.
Familial forms of narcolepsy with several members
of a family affected are rare. A first study, however,
reported a suggestive linkage to chromosome 4p13-
q21 [12] in 8 small Japanese families. In a second
study, from our laboratory, significant evidence for
linkage with a locus in a 5 Mb region of chromo-
some 21q could be established [13].
Narcolepsy is also found in Dobermans and
Labradors and is clinically and electro-physiolog-
ically similar to the human disease. Canine nar-
colepsy is transmitted as a single autosomal reces-
sive trait with full penetrance and is not linked to
the Dog Leukocyte Antigen. After intensive work
over the past 15 years on the genetics of canine 
narcolepsy at Stanford University, Mignot’s group
identified, through linkage analysis and positional
cloning, mutations in the hypocretin-2 receptor 
as the cause of narcolepsy [14]. Simultaneously,
Yanagisawa’s group discovered in the mouse a phe-
notype similar to canine and human narcolepsy
after a targeted deletion of the prepro-hypocretin
gene [15]. The human prepro-hypocretin gene lo-
cated on chromosome 17q21 consists of two exons
and one intron. Hypocretin-1 and -2 are hypothal-
amic neuropeptides and act through hypocretin
receptor-1 and -2 first identified to be implicated
in feeding behaviour. Recently it was discovered
that narcolepsy patients have low or undetectable
hypocretin-1 levels in their CSF [16] and that there
is a dramatic reduction in the number of hypothal-
amic hypocretin-containing neurons in a small
number of post-mortem narcolepsy cases [17].
Also transgenic mice carrying the promoter of the
human prepro-hypocretin gene ligated to trun-
cated human ataxin-3, a gene that induces apop-
tosis of hypocretin containing neurons, present
symptoms similar to human narcolepsy [18]. A sin-
gle presumably pathogenic mutation has been
found in an atypical narcolepsy child [17] but de-
spite the compelling evidence for a causal implica-
tion of the hypocretin system none of the three
genes involved is found mutated in narcolepsy pa-
tients and there is no evidence for any association
between polymorphisms identified in genes en-
coding the prepro-hypocretin and its receptors
and human narcolepsy. Since 90% of human cases
of narcolepsy are sporadic and monozygotic twins
show only partial concordance (25–31%), the de-
velopment of this disease could involve environ-
mental factors interacting with specific genetic
susceptibility factors. Therefore together with the
tight association with the HLA antigens, the most
likely cause of hypocretin deficiency in narcolepsy
might be an autoimmune process resulting in 
acute or progressive degeneration of hypocretin-
containing neurons in the hypothalamus. The 
environmental factor(s) might trigger narcolepsy
by inducing an autoimmune reaction that targets
hypocretin neurons. 
The list of sleep disorders with a genetic con-
tribution is rapidly expending and those reviewed
here constitute significant examples only. Other
common sleep disorders such as insomnia and
nightmares and rare disorders such as idiopathic
hypersomnia might well be controlled by genetic
factors. The most striking finding remains the
HLA association found in narcolepsy, sleepwalk-
ing, Kleine-Levin syndrome, and REM sleep be-
haviour disorder. Although not a single common
feature can be proposed in these disorders, this
finding suggests a fundamental relationship be-
tween sleep and the immune system, which re-
mains to be discovered. The immune system may
modulate brain activity and sleep or at least these
two systems seem to influence each other and in-
teract intimately. Because sleep and sleep disorders
are complex both in their manifestations and reg-
ulation, several approaches are needed to further
our understanding of their molecular basis. Stud-
ies in animal models like drosophila, zebrafish, and
mice could be complemented with genetic linkage
Conclusions
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studies, association studies, and genome-wide
association studies in humans. This could lead to
a better understanding of sleep mechanisms and
ultimately help the development of appropriate
treatments for sleep disorders. 
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